Text Size

Chemoreflex Sensitivity in Chronic Kidney Disease

This study has been completed.
Sponsor:
Collaborators:
Heinrich-Heine University, Duesseldorf
Medical Clinic I, SLK-Kliniken Heilbronn
Information provided by:
RWTH Aachen University
ClinicalTrials.gov Identifier:
NCT00794872
First received: November 19, 2008
Last updated: NA
Last verified: November 2008
History: No changes posted

November 19, 2008
November 19, 2008
January 2007
November 2008   (final data collection date for primary outcome measure)
Hyperoxic chemoreflex sensitivity is impaired in patients with moderate to severe chronic kidney disease [ Designated as safety issue: No ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Chemoreflex Sensitivity in Chronic Kidney Disease
Hyperoxic Chemoreflex Sensitivity in Chronic Kidney Disease

Cardiovascular morbidity and mortality are markedly increased in chronic kidney disease (CKD) and may be explained in part by sympathetic hyperactivity. Impaired hyperoxic chemoreflex sensitivity (CHRS) has been attributed to an increased sympathetic activity. The aim of the present study is to examine whether chemosensor function is altered in patients with stage 3 and stage 4 CKD.

Impaired hyperoxic chemoreflex sensitivity (CHRS) is assessed in patients with stage 3 CKD [glomerular filtration rate (GFR) 30-59 ml/min/1.73 m2], in patients with stage 4 CKD [GFR 15-29 ml/min/1.73 m2], as well as in patients without any evidence of CKD. CHRS is measured by determination of the venous partial pressure of oxygen and the heart rate before and after deactivation of the chemoreceptors by inhalation of pure oxygen. The difference in the R-R intervals before and after inhalation divided by the difference in the oxygen pressures is calculated as the CHRS. A CHRS below 3.0 ms/mmHg is defined as pathological. It should be shown that using a simple clinical bedside test we provide the first evidence for impaired hyperoxic chemoreflex sensitivity in stage 3 and 4 chronic kidney disease. We thereby may lay the basis for future intervention studies assessing chemosensor function in these patients.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Measurement of the venous partial pressure of oxygen in blood samples
Not Provided
Not Provided
  • Chronic Kidney Disease
  • Cardiovascular Morbidity
Other: blood sampling
  • 1
    Patients with stage 3 CKD
    Intervention: Other: blood sampling
  • 2
    Patients with stage 4 CKD
    Intervention: Other: blood sampling
  • 3
    Patients without evidence for CDK
    Intervention: Other: blood sampling
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
65
November 2008
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients suffering from CDK stage 3 (GFR 30-59 ml/min/1.73 m²) or stage 4 (GFR 15-29 ml/min/1.73 m²)
  • For the reference Patients without evidence for CDK

Exclusion Criteria:

  • Patients with heart failure, history of myocardial infarction or instable angina pectoris, atrial fibrillation, hyperthyroidism, chronic pulmonary diseases, sleep apnoea syndrome, alcohol abuse and drug induced cardiomyopathy
Both
18 Years to 90 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00794872
Chemoreflex-Sensitivity-Study
Yes
Christian Meyer, MD, RWTH Aachen University
RWTH Aachen University
  • Heinrich-Heine University, Duesseldorf
  • Medical Clinic I, SLK-Kliniken Heilbronn
Principal Investigator: Christian Meyer, MD RWTH Aachen University Departement of Cardiology, Pulmonology and Vascular Medicine
RWTH Aachen University
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP